Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Inulin-derived adjuvants efficiently promote both Th1 and Th2 immune responses.

Silva DG, Cooper PD, Petrovsky N.

Immunol Cell Biol. 2004 Dec;82(6):611-6. Review.

PMID:
15550119
2.

Novel human polysaccharide adjuvants with dual Th1 and Th2 potentiating activity.

Petrovsky N.

Vaccine. 2006 Apr 12;24 Suppl 2:S2-26-9. Review.

3.

Evaluation of immune response elicited by inulin as an adjuvant with filarial antigens in mice model.

Mahalakshmi N, Aparnaa R, Kaliraj P.

Scand J Immunol. 2014 Oct;80(4):261-70. doi: 10.1111/sji.12208.

4.

Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology.

Honda-Okubo Y, Barnard D, Ong CH, Peng BH, Tseng CT, Petrovsky N.

J Virol. 2015 Mar;89(6):2995-3007. doi: 10.1128/JVI.02980-14. Epub 2014 Dec 17.

5.

Norovirus (NoV) specific protective immune responses induced by recombinant P dimer vaccine are enhanced by the mucosal adjuvant FlaB.

Verma V, Tan W, Puth S, Cho KO, Lee SE, Rhee JH.

J Transl Med. 2016 May 17;14(1):135. doi: 10.1186/s12967-016-0899-4.

6.

Suramin has adjuvant properties and promotes expansion of antigen-specific Th1 and Th2 cells in vivo.

Denkinger M, Shive CL, Pantenburg B, Forsthuber TG.

Int Immunopharmacol. 2004 Jan;4(1):15-24.

PMID:
14975356
7.

Immunomodulation of TH2 biased immunity with mucosal administration of nanoemulsion adjuvant.

Bielinska AU, O'Konek JJ, Janczak KW, Baker JR Jr.

Vaccine. 2016 Jul 25;34(34):4017-24. doi: 10.1016/j.vaccine.2016.06.043. Epub 2016 Jun 23.

8.

Vaccine adjuvants: current state and future trends.

Petrovsky N, Aguilar JC.

Immunol Cell Biol. 2004 Oct;82(5):488-96. Review.

PMID:
15479434
9.

Vaccine adjuvants based on gamma inulin.

Cooper PD.

Pharm Biotechnol. 1995;6:559-80. Review.

PMID:
7551236
10.

Improving the Th1 cellular efficacy of the lead Yersinia pestis rF1-V subunit vaccine using SA-4-1BBL as a novel adjuvant.

Dinc G, Pennington JM, Yolcu ES, Lawrenz MB, Shirwan H.

Vaccine. 2014 Sep 3;32(39):5035-40. doi: 10.1016/j.vaccine.2014.07.015. Epub 2014 Jul 18.

PMID:
25045812
11.
12.

Advax™, a novel microcrystalline polysaccharide particle engineered from delta inulin, provides robust adjuvant potency together with tolerability and safety.

Petrovsky N, Cooper PD.

Vaccine. 2015 Nov 4;33(44):5920-6. doi: 10.1016/j.vaccine.2015.09.030. Epub 2015 Sep 25. Review.

13.

Evaluation of recombinant Onchocerca volvulus activation associated protein-1 (ASP-1) as a potent Th1-biased adjuvant with a panel of protein or peptide-based antigens and commercial inactivated vaccines.

Xiao W, Du L, Liang C, Guan J, Jiang S, Lustigman S, He Y, Zhou Y.

Vaccine. 2008 Sep 15;26(39):5022-9. doi: 10.1016/j.vaccine.2008.07.028. Epub 2008 Aug 19.

14.

Effects of different adjuvants in the context of intramuscular and intranasal routes on humoral and cellular immune responses induced by detergent-split A/H3N2 influenza vaccines in mice.

Baz M, Samant M, Zekki H, Tribout-Jover P, Plante M, Lanteigne AM, Hamelin ME, Mallett C, Papadopoulou B, Boivin G.

Clin Vaccine Immunol. 2012 Feb;19(2):209-18. doi: 10.1128/CVI.05441-11. Epub 2011 Dec 21.

15.

Calcium phosphate nanoparticles as a new generation vaccine adjuvant.

Lin Y, Wang X, Huang X, Zhang J, Xia N, Zhao Q.

Expert Rev Vaccines. 2017 Sep;16(9):895-906. doi: 10.1080/14760584.2017.1355733. Epub 2017 Jul 25. Review.

PMID:
28712326
16.

Polysaccharides: Candidates of promising vaccine adjuvants.

Li P, Wang F.

Drug Discov Ther. 2015 Apr;9(2):88-93. doi: 10.5582/ddt.2015.01025. Review.

17.

Immunopotentiation of Different Adjuvants on Humoral and Cellular Immune Responses Induced by HA1-2 Subunit Vaccines of H7N9 Influenza in Mice.

Song L, Xiong D, Hu M, Kang X, Pan Z, Jiao X.

PLoS One. 2016 Mar 1;11(3):e0150678. doi: 10.1371/journal.pone.0150678. eCollection 2016.

19.

The extracellular matrix protein mindin as a novel adjuvant elicits stronger immune responses for rBAG1, rSRS4 and rSRS9 antigens of Toxoplasma gondii in BALB/c mice.

Sun X, Mei M, Zhang X, Han F, Jia B, Wei X, Chang Z, Lu H, Yin J, Chen Q, Jiang N.

BMC Infect Dis. 2014 Aug 4;14:429. doi: 10.1186/1471-2334-14-429.

20.

The TLR2/6 ligand PAM2CSK4 is a Th2 polarizing adjuvant in Leishmania major and Brugia malayi murine vaccine models.

Halliday A, Turner JD, Guimarães A, Bates PA, Taylor MJ.

Parasit Vectors. 2016 Feb 20;9:96. doi: 10.1186/s13071-016-1381-0.

Supplemental Content

Support Center